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Abstract 
Short communication on t(9;12)(p24;p13) 
ETV6/JAK2, with data on clinics, and the genes 
implicated. 
Clinics and pathology 
Disease 
Myeloproliferative disease in transformation, 
myelodysplastic syndrome (MDS), B-cell acute 
leukemia (B-ALL), and T-cell acute leukemia (T-
ALL). 
Phenotype/cell stem origin 
One B-ALL was CD10+, the two others were not 
otherwise specified.  
The myeloproliferative disease was an atypical 
chronic myelogenous leukemia (a-CML). 
Epidemiology 
Seven patients to date: 5 male and 2 female 
patients. Median age was 26 years (range 1.5-80), 
with two children cases (one B-ALL and one T-
ALL), and four cases were found in young adults 
(aged 25, 26, 32, 33) (Lacronique et al., 1997; 
Peeters et al., 1997; Najfeld et al. 2007; Zhou et al., 
2012). 
Prognosis 
Three patients did not reach complete remission 
(two B-ALL and one T-ALL); one patient died 6 
months after diagnosis (the a-CML case), and one 
patient achieved CR, relapsed; a second CR was 
diagnosis (a B-ALL case). obtained and the patient 
was alive 31 months after 
Cytogenetics 
Cytogenetics morphological 
The t(9;12)(p24;p13) was the sole abnormality in 
three cases, accompanied with a t(3;12) 
ETV6/MECOM in one case, with numerical 
abnormalities in one case, and part of a complex 
karyotype in one case (the MDS case). Del(6q) was 
found in two cases. 
Genes involved and 
proteins 
JAK2 
Location 
9p24.1 
DNA/RNA 
24 exons. 
Protein 
1132 amino acids (aa); from N-term to C-term, 
JAK2 contains: an interaction region with 
cytokine/interferon/growth hormone receptors: aa 
1-239, a FERM domain: aa 37-380, a SH2 domain: 
aa 401-482, two protein kinase domains: aa 545-
809 and 849-1124, an ATP nucleotide binding site: 
aa 855-863, and a loop structure: aa 1056-1078 
(JAK2 kinase insertion loop). JAK homology 
domains are the following: JH7: aa 25-137; JH6: aa 
144-284; JH5: aa 288-309; JH4: aa 322-440; JH3: 
aa 451-538; JH2: aa 543-824; JH1: 836-1123. 
Phosphotyrosines are located at aa 119, 372, 373, 
523, 813, 868, 966, 972, 1007, and 1008 (Harpur et 
al., 1992; Saltzman et al., 1998; Lucet et al., 2006).  
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ETV6/JAK2 fusion protein. 
 
 
Protein tyrosine kinase of the non-receptor type that 
associates with the intracellular domains of 
cytokine receptors; mediates signaling transduction. 
ETV6 
Location 
12p13.2 
DNA/RNA 
9 exons; alternate splicing. 
Protein 
452 amino acids. ETV6 is composed of a HLH 
domain responsible for hetero- and 
homodimerization in N-term, and an ETS domain 
responsible for sequence specific DNA-binding in 
C-term (binds to the DNA sequence 5'-
CCGGAAGT-3'). Transcriptional regulator; tumor 
suppressor. Involved in bone marrow 
hematopoiesis. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
5' ETV6 - 3' JAK2. Three different hybrids have 
been found: fusion of ETV6 exon 4 to JAK2 exon 
17 (Peeters et al., 1997), fusion of ETV6 exon 5 to 
JAK2 exon 17 (Lacronique et al., 1997), and fusion 
of ETV6 exon 5 to JAK2 exon 12 (Peeters et al., 
1997). 
Fusion protein 
Description 
The HLH domain of ETV6 is fused to the protein 
kinase domain(s), the ATP nucleotide binding, and 
the loop structure of JAK2; according to the 
different possible breakpoints, the resulting protein 
contains 475, 654, or 876 amino acids. 
Furthermore, other products result from splicing 
(Peeters et al., 1997). The reciprocal JAK2-ETV6 
may not be expressed. 
Oncogenesis 
It may be speculated that the HLH domain of ETV6 
induces oligomerization, resulting in constitutive 
activation of the kinase domain of JAK2. 
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